Epithelial Borderline Ovarian Tumor: Clinicopathological Features, Outcome and Prognostic Factors

Amornrat Temtanakitpaisan, Pilaiwan Kleebkaow, Apiwat Aue-aungkul


Objective: To evaluate clinic-pathological characteristics, treatment outcomes, factors affecting survival in patients with borderline ovarian tumors (BOTs).

Methods: Medical records of patients with BOTs who had been treated at Srinagarind Hospital during 2001 to 2016 were reviewed. Abstracted data included baseline characteristics, clinic-pathologic features, disease-free survival (DFS), and overall survival (OS).                                                                                  Results: Fifty-two patients with BOTs were included in the study. The mean age+ SD was 41.15+ 15.34 years. Most patients were premenopausal and most common presenting symptom was adnexal mass. Most patients were in early stage (90.4%). Thirty-two patients underwent radical surgery (61.5%). Twenty-one patients (40.3%) underwent lymphadenectomy. An appendectomy was performed in 19 (36.5 %) cases. The median follow-up period was 67.5 months (range, 7 to 180 months). The 5-year and 10-year overall survival rates for all stages were 90% and 85%, respectively. The 5-year and 10-year disease-free survival rates for all stages was 87% and 87%, respectively. Seven (13.5 %) patients had recurrence. Absent residual disease (HR = 0.33; 95 %CI 0.11 – 0.96) and receiving postoperative adjuvant chemotherapy (HR = 0.22; 95 %CI 0.08 – 0.65) were associated factors for DFS.                                                                   Conclusion: The majority of patients with BOTs presented in young age and early stage. Residual lesion and adjuvant chemotherapy are significant factors predicting DFS.                                                       

Full Text:



Silverberg SG, Bell DA, Kurman RJ, Seidman JD, Prat J, Ronnett BM, et al. Borderline ovarian tumors: key points and workshop summary. Human pathology. 2004;35(8):910-7.

Taylor H. Malignant and semi-malignant tumors of the ovary. Surg Gynecol Obstet. 1929;48:204-30.

Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer. 1973;31(5):1031-45.

Hauptmann S, Friedrich K, Redline R, Avril S. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Archiv : an international journal of pathology. 2016.

Pados G, Tsolakidis D, Bili H, Athanatos D, Zaramboukas T, Tarlatzis B. Laparoscopic management of unexpected borderline ovarian tumors in women of reproductive age. European journal of gynaecological oncology. 2012;33(2):174-7.

Denny L, Quinn M. FIGO Cancer Report 2015. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2015;131 Suppl 2:S75.

Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A. Conservative surgery for borderline ovarian tumors: a review. Gynecologic oncology. 2006;100(1):185-91.

Gershenson DM. Clinical management potential tumours of low malignancy. Best practice & research Clinical obstetrics & gynaecology. 2002;16(4):513-27.

Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. European journal of obstetrics, gynecology, and reproductive biology. 2009;142(2):99-105.

Timmerman D, Van Calster B, Testa AC, Guerriero S, Fischerova D, Lissoni AA, et al. Ovarian cancer prediction in adnexal masses using ultrasound-based logistic regression models: a temporal and external validation study by the IOTA group. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2010;36(2):226-34.

Fauvet R, Boccara J, Dufournet C, David-Montefiore E, Poncelet C, Darai E. Restaging surgery for women with borderline ovarian tumors: results of a French multicenter study. Cancer. 2004;100(6):1145-51.

Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007;25(20):2928-37.

Kristensen GS, Schledermann D, Mogensen O, Jochumsen KM. The value of random biopsies, omentectomy, and hysterectomy in operations for borderline ovarian tumors. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2014;24(5):874-9.

Benedet JL, Bender H, Jones H, 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2000;70(2):209-62.

Comert DK, Ureyen I, Karalok A, Tasci T, Turkmen O, Ocalan R, et al. Mucinous borderline ovarian tumors: Analysis of 75 patients from a single center. Journal of the Turkish German Gynecological Association. 2016;17(2):96-100.

Aure JC, Hoeg K, Kolstad P. Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstetrics and gynecology. 1971;37(1):1-9.

Link CJ, Jr., Reed E, Sarosy G, Kohn EC. Borderline ovarian tumors. The American journal of medicine. 1996;101(2):217-25.

Russell P. The pathological assessment of ovarian neoplasms. II: The proliferating 'epithelial' tumours. Pathology. 1979;11(2):251-82.

Segal GH, Hart WR. Ovarian serous tumors of low malignant potential (serous borderline tumors). The relationship of exophytic surface tumor to peritoneal "implants". The American journal of surgical pathology. 1992;16(6):577-83.

Fox H. The concept of borderline malignancy in ovarian tumours: a reappraisal. Current topics in pathology Ergebnisse der Pathologie. 1989;78:111-34.

Boran N, Cil AP, Tulunay G, Ozturkoglu E, Koc S, Bulbul D, et al. Fertility and recurrence results of conservative surgery for borderline ovarian tumors. Gynecologic oncology. 2005;97(3):845-51.

Guvenal T, Dursun P, Hasdemir PS, Hanhan M, Guven S, Yetimalar H, et al. Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study. Gynecologic oncology. 2013;131(3):546-50.

Tinelli R, Malzoni M, Cosentino F, Perone C, Tinelli A, Malvasi A, et al. Feasibility, safety, and efficacy of conservative laparoscopic treatment of borderline ovarian tumors. Fertility and sterility. 2009;92(2):736-41.

Menczer J, Chetrit A, Sadetzki S. The effect of hysterectomy on survival of patients with borderline ovarian tumors. Gynecologic oncology. 2012;125(2):372-5.

Kleppe M, Bruls J, Van Gorp T, Massuger L, Slangen BF, Van de Vijver KK, et al. Mucinous borderline tumours of the ovary and the appendix: a retrospective study and overview of the literature. Gynecologic oncology. 2014;133(2):155-8.

Lin JE, Seo S, Kushner DM, Rose SL. The role of appendectomy for mucinous ovarian neoplasms. American journal of obstetrics and gynecology. 2013;208(1):46.e1-4.

Gokcu M, Gungorduk K, Asicioglu O, Cetinkaya N, Gungor T, Pakay G, et al. Borderline ovarian tumors: clinical characteristics, management, and outcomes - a multicenter study. Journal of ovarian research. 2016;9(1):66.

NCCN. Clinical Practice Guidelines in Oncology Ovarian Cancer. Including Fallopian Tube Cancer and Primary Peritoneal Cancer Version 1. 2016.

Trope CG, Kaern J, Davidson B. Borderline ovarian tumours. Best practice & research Clinical obstetrics & gynaecology. 2012;26(3):325-36.

Winter WE, 3rd, Kucera PR, Rodgers W, McBroom JW, Olsen C, Maxwell GL. Surgical staging in patients with ovarian tumors of low malignant potential. Obstetrics and gynecology. 2002;100(4):671-6.

DOI (PDF (FULL TEXT)): http://dx.doi.org/10.22034/APJCC.2018.3.4.5


  • There are currently no refbacks.

Copyright (c) 2018 Asia Pacific Journal of Cancer Care





Asia Pacific Organization for Cancer Prevention 

West Asia Organization for Cancer Prevention